Cargando…
Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy
Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients. However, no treatment guidelines are available for DKD combined with MN. In this study, we for the first time analyzed the safety and efficacy of leflunomid...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468778/ https://www.ncbi.nlm.nih.gov/pubmed/36111292 http://dx.doi.org/10.3389/fendo.2022.941215 |
_version_ | 1784788492517113856 |
---|---|
author | Shang, Shunlai Cui, Shaoyuan Wang, Wenjuan Wang, Chao Li, Ping Li, Wenge Li, Qinggang |
author_facet | Shang, Shunlai Cui, Shaoyuan Wang, Wenjuan Wang, Chao Li, Ping Li, Wenge Li, Qinggang |
author_sort | Shang, Shunlai |
collection | PubMed |
description | Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients. However, no treatment guidelines are available for DKD combined with MN. In this study, we for the first time analyzed the safety and efficacy of leflunomide (LEF) combined with low-dose glucocorticoid methylprednisolone (MP) in the treatment of DKD with MN. We retrospectively collected the clinical data of patients with the highest number of DKD combined with MN diagnosed by renal biopsy between December 2016 and December 2020. The inclusion criteria were a history of diabetes for more than 20 months, no glucocorticoid therapy or immunosuppressant therapy for at least 6 months, urine protein level greater than 3.5 g, and a follow-up time of 16 months. In addition to conservative treatment, the patients received LEF monotherapy (LEF, n = 38) or LEF combined with low-dose methylprednisolone (LEF+MP, n = 26). After 16 months of treatment, the complete remission rate was 2.6%, and the remission rate was 15.8% in the LEF group; in the LEF+MP group, the complete remission rate and the remission rate were 23.1% and 34.6%, respectively. At month 16, the urine protein level was lower than the baseline value in both groups (p < 0.05) and was significantly lower in the LEF+MP group than in the LEF group (p < 0.05). Serum albumin levels were higher than the baseline value in both groups (p < 0.05), with no significant between-group difference (p > 0.05). No inter- or intragroup difference in serum creatinine or glycated hemoglobin was observed. During treatment, the relapse rate was lower in the LEF+MP group than in the LEF group (p < 0.05). No irreversible adverse events were observed. In summary, LEF+MP is more effective than LEF monotherapy for DKD combined with MN. Large, long-term, randomized, double-blind, controlled studies are needed to further validate the clinical efficacy of LEF+MP. |
format | Online Article Text |
id | pubmed-9468778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94687782022-09-14 Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy Shang, Shunlai Cui, Shaoyuan Wang, Wenjuan Wang, Chao Li, Ping Li, Wenge Li, Qinggang Front Endocrinol (Lausanne) Endocrinology Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients. However, no treatment guidelines are available for DKD combined with MN. In this study, we for the first time analyzed the safety and efficacy of leflunomide (LEF) combined with low-dose glucocorticoid methylprednisolone (MP) in the treatment of DKD with MN. We retrospectively collected the clinical data of patients with the highest number of DKD combined with MN diagnosed by renal biopsy between December 2016 and December 2020. The inclusion criteria were a history of diabetes for more than 20 months, no glucocorticoid therapy or immunosuppressant therapy for at least 6 months, urine protein level greater than 3.5 g, and a follow-up time of 16 months. In addition to conservative treatment, the patients received LEF monotherapy (LEF, n = 38) or LEF combined with low-dose methylprednisolone (LEF+MP, n = 26). After 16 months of treatment, the complete remission rate was 2.6%, and the remission rate was 15.8% in the LEF group; in the LEF+MP group, the complete remission rate and the remission rate were 23.1% and 34.6%, respectively. At month 16, the urine protein level was lower than the baseline value in both groups (p < 0.05) and was significantly lower in the LEF+MP group than in the LEF group (p < 0.05). Serum albumin levels were higher than the baseline value in both groups (p < 0.05), with no significant between-group difference (p > 0.05). No inter- or intragroup difference in serum creatinine or glycated hemoglobin was observed. During treatment, the relapse rate was lower in the LEF+MP group than in the LEF group (p < 0.05). No irreversible adverse events were observed. In summary, LEF+MP is more effective than LEF monotherapy for DKD combined with MN. Large, long-term, randomized, double-blind, controlled studies are needed to further validate the clinical efficacy of LEF+MP. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468778/ /pubmed/36111292 http://dx.doi.org/10.3389/fendo.2022.941215 Text en Copyright © 2022 Shang, Cui, Wang, Wang, Li, Li and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Shang, Shunlai Cui, Shaoyuan Wang, Wenjuan Wang, Chao Li, Ping Li, Wenge Li, Qinggang Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title_full | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title_fullStr | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title_full_unstemmed | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title_short | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
title_sort | retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468778/ https://www.ncbi.nlm.nih.gov/pubmed/36111292 http://dx.doi.org/10.3389/fendo.2022.941215 |
work_keys_str_mv | AT shangshunlai retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT cuishaoyuan retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT wangwenjuan retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT wangchao retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT liping retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT liwenge retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy AT liqinggang retrospectiveanalysisofleflunomideandlowdosemethylprednisoloneforthetreatmentofdiabeticnephropathycombinedwithmembranousnephropathy |